CFMG & Wellpath in California — a documentary investigation · Article 030 of 100 · Series 3 — Physician executives, ownership and succession

Who Chose the Successor Physician? Reconstructing Fithian → Herr → Bazzel

Published

20 September 2026, 6:00 PM PT

Content last changed

20 September 2026, 6:00 PM PT

Public-evidence cutoff

20 September 2026, 6:00 PM PT

Sources checked

20 September 2026, 6:00 PM PT

Record through

20 September 2026, 6:00 PM PT

Editorial status

Public-source editorial review complete

Evidence note. This article relies on public records and distinguishes established fact, party position, allegation, judicial finding, inference and unresolved question. Nothing here is a finding that any identified corporation or individual violated California law unless a cited adjudicative source expressly says so.

Opening frame#

Who Chose the Successor Physician? Reconstructing Fithian → Herr → Bazzel is a governance inquiry, not a title-matching exercise. Corporate office, medical leadership, stock ownership, enterprise employment, and practical decision authority are treated as distinct evidentiary categories. The record is strongest where those categories converge in executed documents and weakest where succession or ownership instruments remain unavailable.

The governing question is narrow: Can officer succession be separated from shareholder succession, and what records would decide it? The article connects that question to juridical identity, operational integration, professional authority, ownership and succession, practical exit rights, and demonstrated veto power only where the evidence makes those connections material.

I. The Question and the Public Record#

The relevant public record is best read cumulatively. No single branding statement, county agenda item, corporate filing, bankruptcy disclosure, or management agreement resolves the entire relationship. The evidentiary value comes from comparing documents created for different purposes and asking whether they converge on the same allocation of identity, authority, economics, and professional responsibility.

What is not known#

No current primary record in the reviewed corpus establishes:

• who owns CFMG shares today;

• exact historical ownership percentages;

• whether Bazzel, Medrano, Kennedy, Herr, Fithian, or Taranath personally held shares at a particular time;

• whether Wellpath can nominate, approve, remove, or replace the physician owner;

• whether Wellpath holds a proxy, option, or forced-transfer right;

• whether CFMG can replace its MSO without ownership consequences.

The rule is locked:

Officer/director status is not shareholder status.

Raymond herr — the longest documented post-founder president#

The public record supports a strong chronology for Herr:

• April 2015 — identified in Shepherd evidence as CFMG Chief Medical Officer and President.

• March 2017 — signs CFMG collective-bargaining agreement as President.

• December 2017 — signs Stanislaus contract as President.

• 2018 — identified by Alameda County as CFMG Chief Medical Officer and President.

• September 2018 — CDPH lists him as President and Chief Medical Officer.

• 2018 — signs Fresno CFMG agreement as President.

• 2020 — appears on Placer agreement as CFMG President.

• September 8, 2021 — signs Monterey Amendment No. 2 as CFMG President.

This is a substantial run of formal corporate/contractual evidence.

It gives Herr an unusually important place in the governance history because his tenure spans:

• the mature H.I.G./CMGC period;

• the 2018 CCS–CMGC combination;

• the creation of the Wellpath brand;

• the 2019 MSA assignment to Wellpath LLC.

The key unanswered question is:

What happened to the CFMG shareholder, board, and Company Designee structure during the 2018–2019 Wellpath transition while Herr was president?

2022 — THE CFMG OFFICER STRUCTURE CHANGES#

By September 2022, public county contracts show a different structure.

A Humboldt County contract was executed by:

• Grady Judson Bazzel, M.D. — President

• Richard Medrano, M.D. — Vice President

A Monterey amendment executed in December 2022 similarly identifies:

• Bazzel as President;

• Medrano as Vice President & Secretary.

Thus the available evidence supports:

Bazzel succeeded Herr as publicly documented CFMG President by September 2022.

The exact corporate action and date remain unknown.

No share transfer should be inferred from this officer succession.

2022–2024 — BAZZEL BECOMES THE CONSISTENT CONTRACT-SIGNING PRESIDENT#

The public county record after the transition becomes much more consistent.

Examples include:

• Humboldt 2022 — Bazzel, President.

• Monterey December 2022 — Bazzel, President.

• Fresno 2023 — Bazzel, President.

• Sonoma labor agreement signed in 2023 — Bazzel, President.

• Solano 2024 — Bazzel, President.

• Tuolumne 2024 — Bazzel, President.

This pattern establishes Bazzel as the principal public CFMG corporate officer before bankruptcy.

The legal question then becomes:

Was he also the Company Designee under the MSA, and what shareholder/director authority stood behind his actions?

That cannot be answered from title alone.

II. Structural and Historical Context#

The correct treatment of the overlap#

the record should not invent a precise succession date from Fithian to Herr.

Possible explanations include:

• Fithian retained a founder/former-president title in pleadings describing earlier events;

• Herr assumed formal presidency during the middle of the decade;

• litigation allegations were historically dated rather than contemporaneous;

• different records used policy or medical titles imprecisely.

Until the corporate minutes and Secretary of State history are obtained, the transition should be described as:

By at least April 2015, Raymond Herr was being identified in contemporaneous operational records as CFMG President and Chief Medical Officer; litigation concerning earlier conduct continued to identify founder Taylor Fithian as President.

That formulation preserves the source conflict rather than silently resolving it.

III. The Control and Governance Analysis#

Documents with the highest evidentiary value#

the investigation should prioritize obtaining and authenticating:

• complete December 31, 2012 MSA;

• all amendments and restatements;

• 2019 assignment documents;

• stock-transfer restriction agreements;

• shareholder succession / replacement agreements;

• CFMG articles, bylaws, shareholder agreements, and board minutes;

• complete list of CFMG shareholders/directors/officers by year;

• “Company Designee” appointments;

• Wellpath/CFMG delegation-of-authority matrices;

• physician hiring and termination workflows;

• physician compensation approval matrices;

• HRIS and payroll audit trails;

• EHR ownership and administrator records;

• clinical policy approval metadata;

• county RFP responses describing management hierarchy;

• malpractice/GL coverage and indemnity instruments;

• outside-counsel retention/claims administration protocols;

• quality assurance and mortality-review governance documents;

• management-fee and intercompany accounting records;

• post-bankruptcy amendments or succession instruments.

Why it matters#

Ricardez is especially important because it reinforces a principle that should govern this entire record:

Do not infer corporate control from private-equity investment alone.

The public case for improper professional control must instead be built from:

• contractual control rights;

• actual decision chains;

• employment authority;

• shareholder succession rights;

• veto/override evidence;

• clinical governance.

The hallman "no ownership overlap" statement is important but not dispositive#

In November 2024, Wellpath board co-chair Kip Hallman told the Santa Barbara Independent that:

• CFMG was a wholly separate entity;

• it was owned primarily by group physicians;

• CFMG contracted with Wellpath for management services;

• the entities had no ownership overlap.

This is among the clearest contemporaneous public descriptions of formal ownership.

Santa Barbara County later described CFMG similarly as a separate physician-owned entity operating in California with a business relationship with Wellpath.

These statements materially undermine allegations that Wellpath or H.I.G. directly held CFMG physician stock.

But the statements do not answer:

• stock-transfer restrictions;

• succession control;

• veto rights;

• contractual replacement rights;

• collateral;

• management dependence;

• practical ability to replace the MSO.

"No ownership overlap" and "no control rights" are different propositions.

Reconstructing shareholder identity YEAR BY YEAR#

County contracts provide some direct corporate-signature evidence.

For example, a 2023 Placer County contract was executed for CFMG by:

• J. Bazzel as President;

• R. Medrano, M.D. as Secretary.

The document expressly invokes California Corporations Code section 313 execution formalities.

This supports the existence of functioning CFMG corporate officers.

The complete governance reconstruction should identify by year:

• shareholders;

• directors;

• president/CEO;

• secretary;

• CFO/treasurer;

• Company Designee;

• medical directors;

• any overlapping Wellpath positions.

The goal is not to imply wrongdoing from overlapping roles.

It is to identify which people actually carried the physician-corporation's legal authority.

THE FITHIAN–HUSTEDT GOVERNANCE MODEL WAS ALREADY MORE COMPLEX THAN A SINGLE PRESIDENT TITLE#

The early record therefore shows at least two distinct forms of CFMG authority:

Taylor Fithian

• founder;

• President;

• Medical Director;

• highly visible physician-policy leader.

Dan Hustedt

• public H.I.G. description: Vice President of Finance;

• MSA execution capacity: Chief Executive Officer of CFMG;

• simultaneously Chief Executive Officer of the management company.

That distinction matters.

The public-facing physician president and the contractual chief executive need not have been the same person.

The governance inquiry should therefore avoid assuming that "President" equals "ultimate corporate authority."

This is precisely why the bylaws and Company Designee records matter.

Post-May 2025 lender-owner era#

New WPCC Parent / reorganized Wellpath owned through a lender restructuring.

CFMG’s professional-corporation form persisted across all three.

That continuity makes CFMG a uniquely useful test case.

The key question is:

Did physician control remain stable while the economic owners of the management enterprise changed, or did CFMG governance adapt to whatever management owner occupied the MSO side?

That question can be answered from board minutes, MSA amendments, stock-transfer agreements, delegation matrices, management-fee changes, and Company Designee records.

Why the stock-transfer document is different from the MSA#

The Management Services Agreement tells us who administers the business.

The stock-transfer agreement may tell us who ultimately controls the owner of the medical corporation.

That distinction is fundamental.

A lawful MSO can perform extensive administrative services for an independently controlled medical corporation.

Examples may include:

• payroll;

• accounting;

• IT;

• HR administration;

• insurance;

• procurement;

• billing;

• compliance support;

• scheduling support;

• records infrastructure;

• contracting support.

The physician corporation can remain substantively independent if the physician owners retain real authority over professional matters and meaningful governance power over the corporation.

A stock-transfer instrument becomes more consequential because it can affect the person who holds the legal voting stock.

If the MSO merely prevents an unqualified person from inheriting professional-corporation stock and provides an orderly mechanism for transfer to another independently selected qualified physician, the agreement may function as a legitimate compliance and continuity device.

If, by contrast, the MSO can decide who owns the PC, replace the owner at will, or cause the owner to lose stock for challenging the MSO, then the agreement can give the MSO leverage over every decision formally assigned to the physician owner.

The legal inquiry therefore changes from:

“Who performs management services?”

to:

“Who can remove the person who is supposed to control the professional corporation?”

The company-designee mechanism is a separate control channel#

Even if the physician shareholders retain unrestricted stock, the MSA can concentrate corporate action in a single CFMG officer.

Section 1.4 provides that the CFMG Chief Executive Officer designated under the bylaws can act as the “Company Designee,” whose action generally constitutes CFMG action under the MSA.

The manager may assume required internal approvals were obtained.

This mechanism can be lawful and efficient.

But it means actual independence may depend heavily on:

• who selects the CEO;

• who can remove the CEO;

• whether that physician is a shareholder;

• whether the CEO has separate Wellpath duties;

• whether the board meaningfully supervises the designee.

Thus the ownership test and Company-Designee test must be joined.

The “affiliated physician” language needs careful analysis#

Wellpath’s bankruptcy filings describe PC owners as licensed physicians “affiliated with” the Debtors.

That phrase is important but ambiguous.

“Affiliated” could describe:

• employment;

• consulting;

• board role;

• management role;

• shared business relationship;

• other contractual connection.

It does not necessarily mean:

• Wellpath shareholder;

• controlled person;

• employee.

For each CFMG shareholder, the record should identify the exact form of affiliation.

If the physician owner simultaneously depends on Wellpath for:

• employment;

• compensation;

• benefits;

• officer title;

• stock eligibility,

the combined leverage may be greater.

If the physician owner has independent professional/economic standing, the governance picture may differ.

"PATIENT SAFETY" IS WHERE ORDINARY HR AND PHYSICIAN GOVERNANCE MEET#

Where a termination or separation communication invokes clinical safety rather than paperwork alone, the decision stops being an ordinary human-resources matter. A statement that a clinician’s return could endanger the clinician or patients is a clinical judgment in substance, whatever its administrative form — and clinical judgment inside a California professional corporation is reserved to the professional entity, not to the management organization that may administer the paperwork around it.

That is why the decision chain matters more than the wording. The question is not whether an administrator may communicate such a decision; plainly one may. The question is whether the professional judgment underlying it was made by the professional corporation before implementation, or supplied afterwards to explain an act already taken. The proper-channel test and the first-decision test answer different halves of that question: the first asks whether the decision travelled through the body actually holding the authority, the second asks whether professional review preceded or followed the operative act.

Neither half can be answered from a communication alone. A letter establishes that a reason was given at a time. It does not establish who held the decision right, what any professional body reviewed, or whether that review was substantive rather than ratificatory. The records that would answer it — committee minutes, written consents, the contemporaneous decision file, the referral path for a fitness-for-duty question — are not in the public record for this project, and this investigation does not infer their contents from the fact that a decision was communicated.

California's Medical Board guidance states that Business and Professions Code section 2400 is intended to prevent unlicensed persons from interfering with or influencing physician professional judgment.

The Board identifies physician-controlled decisions to include:

• diagnostic testing;

• referrals;

• ultimate patient care;

• and how many patients a physician must see or how many hours a physician must work.

It also identifies management decisions that should remain under licensed-physician control when they control medical practice, including:

• selection, hiring, and firing as it relates to clinical competency or proficiency .

The key qualification is the phrase as it relates to clinical competency or proficiency .

Not every termination of a physician is a medical decision.

A professional corporation can use ordinary HR administrators to investigate attendance, payroll, interpersonal conduct, policy compliance, or other nonclinical matters.

An MSO can provide lawful administrative assistance.

But if the operative reason for continued exclusion or termination is:

this physician cannot safely treat patients,

then the investigation must determine whether a licensed CFMG physician independently made or approved that professional judgment.

That is the strongest CPOM-relevant framing currently supported by the record.

It avoids the overbroad proposition that every physician-HR decision must personally be performed by a physician.

H. What are the stock-transfer restrictions?#

The 2019 assignment references related stock-transfer restriction agreements.

The exact documents remain missing from the authenticated primary corpus.

That gap has become more important after the Attorney General's 2026 focus on physician-owner replacement and succession rights.

The defense must be able to show that Wellpath cannot:

• select the CFMG owner;

• compel transfer to its chosen successor;

• veto physician ownership;

• or effectively prevent CFMG from replacing the MSO.

If the restrictions are ordinary professional-corporation compliance devices, production should substantially strengthen the defense.

A right to control ownership would be especially consequential#

The current California enforcement lens matters here.

The Attorney General's pending Art Center position is that contractual rights allowing an unlicensed MSO to replace a physician owner can themselves compromise the independence required by California law.

Carbon Health similarly involved allegations that contractual ownership/succession mechanisms made medical groups effectively captive.

The CFMG record contains a reference to stock-transfer restriction agreements but not the complete instruments.

The control side can therefore argue:

Until those agreements are produced, the investigation's largest structural-control question remains unanswered.

This is not proof that CFMG has a Carbon-style continuity arrangement.

It is the reason the documents are Tier One.

Current working thesis#

CFMG appears to be a real, legally distinct California professional corporation embedded within an exceptionally comprehensive Wellpath management architecture. Formal physician governance, county contracting, nondebtor status, and evidence of professional functions weigh against a simplistic shell-company theory. At the same time, Wellpath’s documented role reaches deeply into physician employment architecture, compensation, staffing, utilization management, records, finance, insurance, contracting, defense, and the succession machinery surrounding the professional-corporation model. The central unresolved question is not whether Wellpath owns CFMG stock—the current evidence does not establish that—but whether contractual and practical rights give the management enterprise power over who may own/control CFMG or over decisions California reserves to physicians.

IV. Contrary Evidence, Limits, and Competing Explanations#

A disciplined analysis must begin its limiting case with the strongest contrary evidence: The central limitation is the missing shareholder/stock-transfer record. Physician corporate titles are genuine governance evidence but are not proof of ownership or independence under disagreement.

DHEERAJ TARANATH is distinct from THE VERIFIED CFMG BOARD#

Dr. Dheeraj Taranath is highly relevant to CFMG operations, but the current evidence does not establish him as a CFMG shareholder, director, or officer.

Wellpath's current leadership page identifies him as:

Chief Clinical Officer, Wellpath

The Wellpath bankruptcy plan likewise listed him among the officers of reorganized Wellpath as Chief Clinical Officer.

County materials in 2026 identify him as a Wellpath chief medical/clinical executive.

He has also communicated on CFMG-related matters.

But those facts do not put him on CFMG's board.

This distinction is important because loose shorthand of the form "physician shareholders and leadership" is easy to apply to any senior clinician associated with the enterprise, including Taranath.

For public publication, that shorthand must not become a factual assertion of share ownership.

The correct description is:

Wellpath Chief Clinical Officer who has participated in CFMG-related clinical/organizational matters; no current public proof of CFMG share ownership or board office identified.

Cfmg’s 2025 physician board is strong contrary evidence to a pure shell theory#

California Secretary of State filings from 2025 identify a physician board consisting of:

• Grady Judson Bazzel, M.D.;

• Richard J. Medrano, M.D.;

• Scott Kennedy, M.D.

This is meaningful.

It demonstrates that CFMG has formal physician directors rather than an openly lay board.

It also distinguishes CFMG from structures in which the MSO itself directly holds board seats in the professional corporation.

The unresolved issue is not whether physicians appear in governance.

It is whether those physician directors were free to act independently where their judgment diverged from Wellpath.

That is why real board minutes, rejected recommendations, stock rights, and conflict procedures matter.

Physician participation in personnel decisions is an open question, not a finding#

Whether physician directors participated in any particular personnel decision is a governance question the public record does not yet answer. Absent contemporaneous minutes, written consents or a decision file, the reviewed public materials do not establish physician-board participation in any individual employment action.

The methodological point remains important. If physician participation is later established through a public filing, sworn testimony, or authenticated governance record, it would be meaningful evidence against any categorical claim that physicians never participate in CFMG decision-making. Its institutional weight would still depend on the body's charter, delegated authority, timing, information set, ability to choose a different outcome, and control over implementation.

Accordingly, the public investigation should neither erase possible physician involvement nor overstate it. It should acquire the governance documents capable of showing whether physician review is advisory, ratifying, or genuinely final when management and professional judgment diverge.

V. Missing Documents and Falsification Tests#

The record remains incomplete in material respects. Key unresolved points include the actual shareholder ledger, stock-transfer agreement, succession minutes, and the explanation for contradictory parent/subsidiary/affiliate filings.

Layer eleven: the 2019 assignment and stock-transfer restrictions#

The January 2019 assignment is one of the most consequential public documents.

It transferred the management agreement to Wellpath LLC.

It also says the assignment included related or incidental instruments, including relevant stock transfer restriction agreements .

That phrase should be handled with care.

It establishes a documentary trail.

It does not establish what rights the stock-transfer instruments contained.

The public investigation should therefore resist the temptation to fill the gap with facts from unrelated “friendly PC” cases.

Instead, the proper question is simple:

What do the CFMG-specific stock-transfer and succession documents actually say?

Until those documents are located, the answer remains open.

MBC / OMBC / BRN#

The stock-control question has moved to the top tier#

The 2019 assignment references related stock-transfer restriction agreements.

California’s 2026 enforcement posture makes those documents potentially decisive.

The principal questions are:

• Who selects a successor CFMG shareholder?

• Can Wellpath/MSO nominate, approve, veto, remove, or cause replacement of a physician shareholder?

• Is there a transfer-restriction agreement, succession agreement, proxy, option, nominee arrangement, succession list, or irrevocable power?

• What happens to shares when a physician owner dies, resigns, loses licensure, or leaves employment?

• Who controls the purchase price?

• Who funds the purchase?

• Does the MSO hold security interests or contractual rights tied to the shares?

• Can CFMG terminate the MSA without losing critical systems, staff, brand, financing, or contracts?

• Can a CFMG shareholder remove Wellpath as manager in practice?

The difference between economic dependence and legal control must be preserved.

A PC can be economically dependent on an MSO without the MSO legally owning it. But if the MSO controls who may own or govern the PC, California regulators may view the arrangement very differently.

The bankruptcy did not reorganize CFMG stock through the debtor plan#

Because CFMG was a nondebtor professional corporation, the Wellpath Chapter 11 did not simply convert CFMG stock into lender equity in the manner that debtor-company equity was restructured.

That distinction matters.

Wellpath itself announced in May 2025 that ownership of the reorganized Wellpath enterprise transitioned to a group of current and former lenders.

Public SEC filings by Prospect Capital show that its Wellpath debt was converted into debt and equity positions in New WPCC Parent, LLC . Prospect subsequently reported holdings including Series A Preferred Interests and Class A Common Interests in New WPCC Parent.

Those records illuminate the new ownership of the management enterprise.

They do not establish that New WPCC Parent owns CFMG's physician stock.

The more precise question is:

What happened to the MSA, stock-transfer restrictions, management rights, security interests, and succession mechanisms when the Wellpath management enterprise changed ownership?

That is the post-bankruptcy continuity issue.

Shareholder#

The shareholder owns the professional corporation's stock.

Because CFMG is a California professional medical corporation, stock ownership is subject to California professional-corporation restrictions.

A shareholder's identity must be established through:

• stock ledger;

• stock certificate;

• shareholder agreement;

• transfer record;

• corporate minutes;

• authenticated corporate filing or admission.

A title alone is insufficient.

What it does not establish#

It does not by itself establish:

• that he owned CFMG shares;

• that the agreement was invalid;

• that CFMG lacked physician shareholders;

• that he made medical decisions;

• that California's CPOM doctrine was violated.

Affiliated entities can have overlapping officers.

But in a structure whose legality turns on professional-corporation independence, dual corporate roles increase the importance of independent corporate authorization.

The missing records are therefore:

• CFMG board resolution approving the MSA;

• shareholder approval, if any;

• conflict disclosure;

• independent legal review;

• bylaws;

• Company Designee appointment;

• minutes documenting physician deliberation.

Section 313 signature records are strong officer evidence#

Several county agreements contain explicit California Corporations Code section 313 execution language.

For example, Placer's contract states that a corporation should be signed by officers from specified statutory categories unless a board resolution authorizes otherwise.

Those records are valuable because they provide stronger evidence of corporate office than casual website biographies.

Thus:

• Herr signing as President;

• Bazzel signing as President;

• Medrano signing as Vice President/Secretary;

• Kennedy signing as VP/Treasurer;

should be treated as significant corporate acts.

They still do not establish share ownership.

The central refinement to the current governance narrative#

Older shorthand:

"Bazzel, Medrano, Kennedy and Taranath are CFMG physician shareholders."

Better:

California Secretary of State records verify Bazzel, Medrano and Kennedy as CFMG officers and directors in 2025. Public records verify Taranath as Wellpath's Chief Clinical Officer. The current public evidence does not identify CFMG's shareholder roster or establish Taranath as a shareholder.

That distinction should be locked into future drafts.

Where the missing stock documents may exist#

Potential repositories include:

• CFMG corporate minute book;

• corporate counsel records;

• Wellpath legal department;

• management-company contract repository;

• bankruptcy diligence/data room;

• H.I.G. transaction files;

• lender diligence files;

• UCC/collateral documentation;

• former officer records;

• county due-diligence submissions if ownership certifications were required;

• malpractice/insurance underwriting files;

• California regulatory filings;

• tax records.

The 2019 assignment proves that at least some stock-transfer restriction instruments existed.

That makes their absence from the public record a retrieval problem, not a reason to assume their contents.

2025 SECRETARY OF STATE FILINGS SHOW A PHYSICIAN BOARD DURING THE BANKRUPTCY ERA#

Project records from the California Secretary of State identify, in January 2025:

• Grady Judson Bazzel — Chief Executive Officer / Director;

• Richard J. Medrano — Secretary / Director;

• Scott Kennedy — Chief Financial Officer / Director.

That means the formal CFMG board during the bankruptcy period was physician-composed.

This is meaningful evidence favoring the formal professional-corporation structure.

It also allows the governance question to be framed concretely:

What did Bazzel, Medrano, and Kennedy decide, in their CFMG capacities, about the Chapter 11 and continuation of the Wellpath MSA?

That is much more useful than asking abstractly whether “CFMG” approved the reorganization.

WHAT WOULD CONSTITUTE STRONG CONTRARY EVIDENCE?#

The following would be substantially more consequential:

• Wellpath or lender documents selecting CFMG’s shareholder successor without meaningful physician choice;

• stock-transfer instruments requiring continuation of Wellpath as manager;

• CFMG board action occurring only after Wellpath implementation;

• automatic continuation of the MSA despite a formal assignment/ownership change requiring consent;

• documents showing the Wellpath side could replace the CFMG owner/director;

• lender covenants directly controlling CFMG governance;

• CFMG unable to terminate the manager without losing its stock, contracts, accounts, records, or operating assets.

No such CFMG-specific document has yet been established publicly in this investigation.

That is precisely why the missing stock and governance instruments matter.

High-priority bankruptcy documents for the next pass#

• Docket No. 194 and its complete potential-assumed-contract schedule.

• All supplements to Docket No. 194.

• Docket Nos. 2039, 2189, 2498, and 2551 rejection schedules.

• Plan Supplement Docket Nos. 2321 and 2555.

• First Amended Plan Docket No. 2376-1 and technical modifications Docket No. 2552-1.

• Schedule of assumed executory contracts at emergence.

• Any specific entry for the CFMG MSA.

• Any CFMG cure amount.

• Any notice served directly on CFMG.

• Any CFMG objection, reservation, consent, or response.

• Any stock-transfer agreement listed as executory.

• Any CFMG organizational document listed as executory.

• Any post-effective-date assumption/assignment of the CFMG MSA.

• New WPCC Parent LLC agreement.

• lender governance/board-appointment rights.

• restructuring-transaction steps involving Wellpath LLC / Wellpath Management.

• documents concerning Wellpath CFMG, Inc. f/k/a CFMG Holdings Corp. to preserve entity distinctions.

• CFMG board minutes November 2024–June 2025.

• CFMG shareholder minutes during restructuring.

• CFMG independent-counsel engagement records.

• post-emergence CFMG MSA amendments.

• 2026 Local Government–California authority/delegation records.

The bankruptcy record sharpens the central cpom question#

The bankruptcy evidence does not prove that Wellpath practiced medicine through CFMG.

It does something more useful.

It reveals the architecture of dependence .

The Debtors themselves described:

• a friendly-PC structure;

• physician ownership;

• deep administrative control;

• major economic reliance on PC revenues;

• stock-transfer restrictions tied to management continuity;

• authority relating to PC licensing/qualification;

• insurance;

• payroll;

• collections;

• taxes;

• legal support;

• indemnification;

• lender notice over new PC contracts.

California law then asks a separate question:

Did those structural rights and dependencies remain on the lawful administrative side of the line, or did they give the nonprofessional management enterprise practical or contractual authority over decisions reserved to physicians?

That question still requires the CFMG-specific stock, board, and authority records.

Current confidence assessment#

2019 Assignment made Wellpath LLC the manager: Very High.

January 2019 CFMG MSA remained operative in February 2025: Very High.

Final Plan used blanket assumption as default: Very High.

California Forensic Medical Group absent from final searchable rejection schedule: High, subject to indexing/name limitations.

No reviewed earlier rejection notice identifies CFMG: High, subject to the same caveat.

Another PC relationship was affirmatively rejected: Very High.

CFMG MSA was therefore deemed assumed on May 9, 2025: High-confidence documentary/legal inference.

Wellpath LLC remained applicable contracting post-restructuring manager: High.

A new public assignment to New WPCC Parent was required: Not supported.

New WPCC Parent acquired CFMG physician stock: Not established.

CFMG expressly consented to the assumption: Unknown.

CFMG board independently deliberated about continuing Wellpath: Unknown from public record.

CFMG stock-transfer restriction agreement survived through Article V.F: Plausible and important inference; not yet proven from the exact instrument.

Bankruptcy makes the control-instrument question more urgent#

the prior analysis indicates that the CFMG MSA most likely continued through Wellpath’s Chapter 11 under the Plan’s blanket assumption mechanism.

The 2019 assignment also placed stock-transfer restrictions in the Wellpath LLC relationship.

The confirmed Plan contains broad language treating assumed contracts as including related agreements and interests unless separately rejected.

This creates a plausible path by which stock-control rights could have continued after May 9, 2025.

But the precise bankruptcy treatment of the CFMG stock agreement remains unknown.

Questions:

• Was the stock agreement separately scheduled?

• Was it considered an executory contract?

• Was it considered an organizational document?

• Was it amended at emergence?

• Did lender ownership alter any rights?

• Did the physician shareholder sign a reaffirmation?

These questions should be treated as Plan implementation issues, not merely historical corporate questions.

Specific document request language#

A targeted request should seek:

All stock transfer agreements, stock transfer restriction agreements, shareholder succession agreements, continuity agreements, assignable options, stock powers, proxies, powers of attorney, nominee agreements, escrow agreements, buy-sell agreements, and related amendments concerning any shares of California Forensic Medical Group, Incorporated, including all agreements assigned or referenced in the January 1, 2019 Assignment of Management Services Agreement.

It should also request:

All documents identifying any person or entity with authority to nominate, approve, reject, remove, replace, or designate a CFMG shareholder, director, officer, Chief Executive Officer, or Company Designee.

That language is considerably more precise than requesting “ownership records” generically.

The physician-governance body remains undocumented#

Public corporate records identify CFMG physician directors and officers. Whether the same individuals participated in particular personnel decisions is not established by any public record reviewed here. This analysis therefore does not publish the private worker, date, outcome, or underlying personnel document.

The governance question is nevertheless legitimate and independently testable:

What is the legal source, charter, membership, delegated authority, and decision scope of any CFMG body described as a physician board, physician committee, peer-review body, or comparable professional-governance group?

The answer should be sought in public or otherwise publishable versions of:

• bylaws;

• board resolutions;

• committee charters;

• delegation instruments;

• minutes or written consents filed in litigation;

• credentialing/peer-review governance documents;

• and sworn testimony describing the body's authority.

Until those materials are located, the correct public conclusion is that CFMG has identifiable physician corporate leadership while the relationship among its statutory board, any physician committee, and other professional-governance bodies remains incompletely documented.

Records with the highest probative value#

• articles of incorporation;

• bylaws, all relevant versions;

• shareholder agreements;

• stock certificates and ledgers;

• stock-transfer restriction agreements;

• succession agreements;

• options;

• proxies;

• voting agreements;

• nominee agreements;

• custodial/escrow agreements;

• death/disability succession instruments;

• buy-sell agreements;

• board/shareholder resolutions approving ownership arrangements;

• 2012 MSA and all exhibits;

• assignment into Wellpath structure;

• every amendment/restatement/waiver;

• deficit-funding agreements;

• collateral/security agreements;

• UCC filings;

• deposit-account control agreements;

• MSA termination notices/rights analyses;

• documents addressing transition away from the manager.

Permanent wording / correction rules#

• Never conflate California Forensic Medical Group, Incorporated with Wellpath CFMG, Inc. f/k/a CFMG Holdings Corp.

• Never call Bazzel, Medrano, Kennedy, Taranath, Herr, Fithian, or another physician a CFMG shareholder without stock evidence.

• Do not state that H.I.G. directly purchased CFMG professional-corporation stock absent acquisition/stock records.

• Do not treat Wellpath bankruptcy language referring to “ownership interests” as an admission that Wellpath owned CFMG stock.

• Do not say the 2025 Plan assigned the CFMG MSA “to the lenders.” Current best reconstruction is continued Wellpath LLC counterparty + Plan assumption/revesting + new upstream ownership.

• Treat Art Center and Carbon Health as California legal/enforcement comparators, not adjudications against CFMG.

• Treat county phrases such as “CFMG/Wellpath,” “now Wellpath,” and “dba Wellpath” as evidence of client/public understanding, not dispositive corporate genealogy.

• Treat \*Smith\*’s same-entity stipulation as binding in that case, not universal merger/alter-ego proof.

• Treat Reynolds , Johnson , Pugh , J.S. , Yang , and similar post-bankruptcy corrections as strong entity-separateness evidence.

• Treat Rule 30(b)(6) use of a Wellpath employee as institutional-knowledge evidence, not automatic alter ego.

• Always distinguish participation , recommendation , approval , veto , implementation , and blocking power .

VI. Why the Issue Matters#

The stakes are practical rather than semantic. Counties need to know which entity is accountable for contracted performance; clinicians need to know where professional authority resides; courts and regulators need entity-specific evidence rather than brand shorthand; and the public needs a record that distinguishes corporate continuity from operational integration. Those distinctions become most important when the actors disagree, when a contract changes hands, when a professional decision conflicts with an economic preference, or when litigation requires a precise answer to who had authority to act.

VII. Falsification Tests and Evidentiary Limits Note#

The record does not support be read as establishing an unproven motive, an undisclosed shareholder, an unlawful medical override, or a legal conclusion that a court or regulator has not made. The strongest version of the thesis is the one that survives the missing-document test: identify the instrument, minutes, ledger, delegation, approval record, or disagreement event that would materially change the conclusion, then state what has and has not been found. If later primary evidence contradicts a proposition stated here, the correction should be made at the proposition level rather than defended through branding or organizational shorthand.

VIII. Related Articles#

• Article 029 — Did CFMG Own Wellpath LLC? The Federal 'Corporate Parent' Disclosure Anomaly

• Article 031 — Fresno County: A $400 Million-Scale Contract and a Multi-Layer Authority System

• Article 028 — The Missing Stock-Transfer Agreement

The proposition to be tested#

The central proposition in this article is not that every appearance of the Wellpath name proves control, nor that formal CFMG separateness ends the inquiry. The proposition to be tested is narrower: Can officer succession be separated from shareholder succession, and what records would decide it? A serious legal brief should state that proposition before discussing motive, liability, or remedy because the same document can be highly probative on one dimension and nearly irrelevant on another.

For this subject, the principal evidentiary dimensions are officer succession, shareholder succession, appointment power, and corporate records. The source spine identified in the current public record is: Officer chronology; stock-transfer references; board/shareholder minutes missing; Company Designee; current governance. Those sources should not be pooled as though they were interchangeable. A county contract speaks most reliably to the county's counterparty and purchased obligations. A management agreement speaks to contractual allocation between the professional corporation and manager. A court order speaks to the matter actually adjudicated. A party filing or corporate announcement remains a representation unless independently adopted or found by a tribunal.

Governance evidence must distinguish office, employment, management title, board membership, shareholder status, delegated authority, and signature authority. These categories can overlap in one person without becoming legally interchangeable. The relevant capacity must be identified for each act. The practical advantage of that method is that it prevents a common failure in complex-enterprise investigations: using a true fact about one relationship as proof of a different relationship. A shared brand may show integration; a W-2 may show payroll identity; a contract signature may show authority to bind a corporation; an officer title may show corporate office. None automatically proves stock ownership or final clinical authority.

The charging or enforcement threshold, if any regulator ever considered one, would therefore require an evidence chain rather than a collage: identify the protected or regulated function; identify the actor with formal authority; reconstruct the first operative decision; identify the person or entity that could approve, reject, modify, or reverse it; and verify who implemented the result. Until that chain is complete, the proper classification is evidence, inference, or unresolved question—not adjudicated fact.

Weighing the evidence#

The evidentiary hierarchy for Who Chose the Successor Physician? Reconstructing Fithian → Herr → Bazzel should begin with contemporaneous primary instruments and end with retrospective shorthand. Executed contracts, amendments, assignments, board resolutions, authenticated corporate records, court orders, government payroll or labor records, and formal agency records ordinarily deserve more weight on the proposition they were created to establish than marketing language or later summaries. Even among primary materials, however, purpose matters. A contract can establish contractual rights without proving that those rights were exercised; a tax record can establish reporting without deciding every common-law employer factor; a bankruptcy schedule can establish debtor treatment without answering professional-governance questions for a nondebtor corporation.

The article's existing record illustrates why that hierarchy matters.ithin its evidentiary lane. What happened to the CFMG shareholder, board, and Company Designee structure during the 2018–2019 Wellpath transition while Herr was president?

A prosecutor, defense lawyer, regulator, or investigative editor should ask five questions of every source: Who created it? What legal or business purpose did it serve? What date and entity does it concern? Is the statement a recital, operative term, allegation, stipulation, finding, or marketing representation? What independent record could confirm or contradict it? Applying those questions consistently is more valuable than multiplying citations that all derive from the same underlying assertion.

This also defines how contradictions should be handled. When two records use different labels, the first step is not to accuse one of being false. The first step is to determine whether the records were answering different questions. Only after normalizing entity, date, capacity, forum, and purpose should a remaining contradiction be treated as substantive. That discipline makes the article stronger for both sides because it identifies where the record genuinely conflicts and where the conflict is merely semantic.

Chronology as a control test#

Chronology is often more probative than organizational charts. The decisive question is not merely who possessed authority on paper, but when a decision became operative and what happened immediately before and after that moment. A later board vote, HR notice, county communication, or litigation position may confirm, ratify, or explain an earlier act without proving who made the initial decision. Conversely, an early recommendation may have no legal effect until the authorized professional or contracting entity adopts it.

For Who Chose the Successor Physician? Reconstructing Fithian → Herr → Bazzel, the chronology should be reconstructed with document-level precision. Investigators should place each significant contract, amendment, email that has entered the public record, board action, personnel or agency event that is lawfully publishable, and court filing on a single timeline. Each entry should identify the actor, capacity, entity, action verb, and legal effect. Terms such as “recommended,” “approved,” “directed,” “implemented,” “ratified,” “reported,” and “terminated” are not synonyms. The wording can reveal whether a participant supplied information, exercised discretion, or merely carried out another actor's decision.

The current article supplies anchor points that should remain central. By at least April 2015, Raymond Herr was being identified in contemporaneous operational records as CFMG President and Chief Medical Officer; litigation concerning earlier conduct continued to identify founder Taylor Fithian as President. Santa Barbara County later described CFMG similarly as a separate physician-owned entity operating in California with a business relationship with Wellpath.

A robust chronology is also the best protection against overstatement. If the alleged controlling act occurred before the supposedly controlling actor entered the process, that theory weakens. If a professional body acted only after implementation, a claim that it supplied the first operative decision requires qualification. If the public record shows independent deliberation before implementation, that evidence materially strengthens the formal-independence account. The analysis therefore must treat time as an evidentiary variable, not just background narrative.

How each source is used#

The following public authorities are tied to defined propositions in this article. They are not interchangeable: each is cited for the institutional purpose it can actually prove, and none is treated as a universal finding about ownership, employment, liability, or professional control.

• H.I.G. Capital, 'H.I.G. Capital Announces Strategic Investment in California Forensic Medical Group,' Jan. 7, 2013. Used here as first-party transaction evidence for the 2013 investment and founder-era enterprise history, but not a shareholder ledger for the California professional corporation.
• 2012 CFMG Management Services Agreement — California Forensic Medical Group, Incorporated and California Forensic Management Group, Inc., Dec. 31, 2012. Used here as operative baseline for the allocation of management functions, physician-reserved responsibilities, and the manager/professional-corporation relationship.
• 2019 Assignment of Management Services Agreement, effective Jan. 1, 2019 — CFMG remained the Company while Wellpath LLC became the Manager. Used here as dated evidence of management succession without, by itself, eliminating CFMG's separate professional-corporation identity.
• Wellpath, 'Wellpath Announces Creation of a New Operating Division in California,' Mar. 13, 2026. Used here as Wellpath's current public description of its California operating layer and its relationship with CFMG.
• Medical Board of California, Practice Information / Corporate Practice of Medicine guidance. Used here as California regulator guidance identifying physician-reserved decisions and limits on delegation of professional judgment to management organizations.
• California Corporations Code § 13401.5, Moscone-Knox Professional Corporation Act. Used here as the professional-corporation ownership and licensed-person framework relevant to shareholder, director, officer, and professional-employee questions.
• Johnson v. County of Alameda, N.D. Cal. No. 3:23-cv-04069, ECF No. 76 (Mar. 2026). Used here as a public litigation correction distinguishing CFMG from Wellpath Management, Inc. and the debtor-side entities.

Sources and authorities#

1. H.I.G. Capital, 'H.I.G. Capital Announces Strategic Investment in California Forensic Medical Group,' Jan. 7, 2013 — https://hig.com/news/h-i-g-capital-announces-strategic-investment-in-california-forensic-medical-group/
2. 2012 CFMG Management Services Agreement — California Forensic Medical Group, Incorporated and California Forensic Management Group, Inc., Dec. 31, 2012 — https://www.prisonlegalnews.org/news/publications/california-forensic-medical-group-incorporated-management-services-agreement/
3. 2019 Assignment of Management Services Agreement, effective Jan. 1, 2019 — CFMG remained the Company while Wellpath LLC became the Manager — https://www.prisonlegalnews.org/media/publications/California\_Forensic\_Medical\_Group\_Assignment\_of\_Management\_Services\_Agreement.pdf
4. Wellpath, 'Wellpath Announces Creation of a New Operating Division in California,' Mar. 13, 2026 — https://wellpathcare.com/2026/03/13/wellpath-announces-creation-of-a-new-operating-division-in-california-appoints-new-highly-experienced-leader/
5. Medical Board of California, Practice Information / Corporate Practice of Medicine guidance — https://www.mbc.ca.gov/Licensing/Physicians-and-Surgeons/Practice-Information/
6. California Corporations Code § 13401.5, Moscone-Knox Professional Corporation Act — https://leginfo.legislature.ca.gov/faces/codes\_displaySection.xhtml?lawCode=CORP&sectionNum=13401.5.
7. Johnson v. County of Alameda, N.D. Cal. No. 3:23-cv-04069, ECF No. 76 (Mar. 2026) — https://docs.justia.com/cases/federal/district-courts/california/candce/3%3A2023cv04069/416712/76

Citation rule: These sources support only the propositions identified in the article and source analysis. A party filing remains a party position unless adopted by a court; a corporate announcement remains a corporate representation; a contract proves allocated rights but not necessarily implementation; and a regulator's guidance or enforcement position is not an adjudication against CFMG unless a cited matter says so.